| Wirkstoff
| Handelsname
| Wirkmechanismus
| Unternehmen
| MS Form
|
| Phase-III: Zulassungsstudien
|
| BG12/Fumarsäure | Panaclar® | TH1 -> TH2 Shift | BiogenIdec | RRMS
|
| Alemtuzumab | Campath® | Eliminierung von Lymphozyten und Monozyten | Genzyme/BayerSchering | RRMS
|
| Glatirameracetat 40mg | Copaxone® | | Teva/SanofiAventis | RRMS
|
| Fingolimod (FTY-720) | | Sphingosin-1-phosphat-Modulator | Novartis | RRMS
|
| Laquinimod (ABR-215062) | | | Teva/Active Biotech | RRMS
|
| MBP8298 | | MBP-Immuntoleranz | BioMS | SPMS
|
| Mycophenolat-Mofetil + Interferon | CellCept® | | Roche |
|
| Cladribin oral | Movectro® | Eliminierung von Lymphozyten und Monozyten | Merck Serono |
|
| Progesteron + Estradiol | | | Hospices Civils de Lyon |
|
| Interferon Beta 1a neue Formulierung | Rebif® | | Merck Serono |
|
| Cyclophosphamid Hochdosis | Revimmune® | Neuaufbau des Immunsystems | Accentia Biopharmaceuticals |
|
| Rituximab | Rituxan® | Eliminierung von B-Zellen | BiogenIdec/Genentech | PPMS
|
| Autologe Stammzelltransplantation | | Neuaufbau des Immunsystems | ASTIMS-Studie |
|
| TCV-01-002 | | T-Zell-Impfung; Elimierung autoreaktiver T-Zellen | Sheba Medical Center |
|
| Teriflunomid (HMR 1726) | | Verhindert T- und B-Zell Vermehrung | SanofiAventis |
|
| Estradiol + Glatirameracetat | Trimesta® | | Pipex Pharmaceuticals |
|
| Phase-II: Studien zur Dosierung und Wirksamkeit
|
| Albuterol + Glatirameracetat | Proventil® | | |
|
| Alferon N Injektionen | | | Hemispherx Biopharma |
|
| IDEC-131 | | Anti-CD154 | Dartmouth |
|
| ATL-1102 | | α4-Integrin-Hemmer | Antisense Therapeutics |
|
| BCG Impfung | | | |
|
| BHT-3009 | | DNA-Plasmid-Impfung | Bayhill Therapeutics | RRMS
|
| Cannabinoide oral | | | Clin. Neur. Research Group - Plymouth | PPMS
|
| CDP323 | | α4-Integrin-Hemmer | UCB / BiogenIdec |
|
| Chaperonin 10 | XToll® | | C-Bio |
|
| Daclizumab | Zenapax® | | Protein Design Labs, BiogenIdec |
|
| Doxycycline + Interferon | | | |
|
| Enkorten | FAR404® | | Farmacija |
|
| Erythropoietin | EPO® | | Stem Cell Therapeutics |
|
| Estroprogestin + Interferon | | | S. Andrea Hospital |
|
| Firategrast (SB683699/T-0047) | | α4-Integrin-Hemmer | GlaxoSmithKline/Tanabe | RRMS
|
| Fluoxetine | Prozac® | | University Medical Center Groningen | SPMS / PPMS
|
| GEM-SP | | | Gemacbio | SPMS
|
| Ibudilast (MN-166) | | PDE4-Hemmer | Medicinova |
|
| Immunmodulation durch Darmparasiten | | | Univ. of Wisconsin |
|
| IL-12/23 mAb | | | Dartmouth-Hitchcock Medical Center |
|
| Inosine | | | Thomas Jefferson University |
|
| Interferon alpha oral | | | University of Texas-Houston |
|
| Interferon-tau | Tauferon® | | Pepgen |
|
| Kynurenine | Tranilast®, Rizoben® | | Nuon Therapeutics |
|
| Lamotrigin | Lamictal® | | GlaxoSmithKline | SPMS
|
| Liponsäure + Interferon | | | OHSU |
|
| Low-dose Naltrexone | LDN® | | UCSF |
|
| Atorvastatin | Lipitor® | | Pfizer |
|
| Azathioprin + Prednison | | | Univ. of Chicago |
|
| Mesenchymale Stammzellen | | | Univ. of Cambridge |
|
| Methotrexate intrathecal | | | |
|
| Nerispirdine (ehem. HP184) | | | SanofiAventis |
|
| Minocycline + Glatirameracetat | | | |
|
| Minocycline + Interferon | | | |
|
| MLN1202 | | CCR2-Antagonist | Millenium |
|
| N-acetyl-L-Cystein + Glatirameracetat | | | |
|
| | Neurovax | | Orchestra Therapeutics |
|
| Ofatumumab | HuMax-CD20® | | Genmab |
|
| Omega-3 Fettsäuren | | | Norwegen |
|
| Pioglitazone | | | Actos |
|
| Pirfenidone | Deskar® | | Intermune |
|
| Pixantron (BBR 2778) | | | Cell Therapeutics |
|
| Pravastatin | | | Nantes Univ. Hospital - France |
|
| RG2077 | CTLA4-IgG4m | | Immune Tolerance Network and Repligen |
|
| Riluzole + Interferon | | | UCSF |
|
| Rituximab | Rituxan® | | Biogen / Genentech | RRMS
|
| RPI-78M | | | Nutra Pharma / ReceptoPharm |
|
| Stammzellen | | | European Charcot Foundation |
|
| T-Zell Impfung | | | Transnational University Limburg |
|
| Temsirolimus | CCI-779, Torisel® | | Wyeth |
|
| Testosteron | | | UCLA |
|
| Topiramate + Interferon | Topamax® | | Cell Therapeutics |
|
| T-Zell Impfung | Tovaxin® | | Opexa |
|
| Treosulfan | | | Univ. Würzburg | SPMS
|
| Vitamin D3 + Calcium | | | St. Michael's Hospital - Toronto |
|
| Simvastatin | Zocor® | | Merck |
|
| Phase-I: Studien zur Verträglichkeit
|
| AVE9897 | | | SanofiAventis |
|
| AZD5904 | | | AstraZeneca |
|
| BCX-4208 | | | BioCryst and Roche |
|
| Cannabinor | | | Pharmos |
|
| CCX915 | | CCR2 Antagonist | ChemoCentryx |
|
| EGCG | | | Charite Berlin |
|
| Extracorporeal photochemotherapy | | | University of Milano-Bicocca |
|
| INCB8696 | | | Incyte |
|
| JNK Inhibitor | | | Serono |
|
| MDX1100 | | | Medarex |
|
| MLN0415 | | | Millenium / SanofiAventis |
|
| MM-093 | | Human Alpha-Fetoprotein | Merrimack |
|
| MMP-12 Inhibitor | | | Medarex |
|
| NNZ-2566 | | | Neuren |
|
| NI-0401 | | | NovImmune |
|
| PI-2301 | | | Peptimmune |
|
| R1295 | | | Roche |
|
| RTL1000 | | T-Zell Rezeptor Ligand | Artielle ImmunoTherapeutics |
|
| SC12267 | | | 4SC AG |
|
| SGN-30 | | nti-CD30 mAb | Seattle Genetics |
|
| Sildenafil Citrate | Viagra® | | Pfizer |
|
| TK54 | | | LTKfarma |
|
| Vor-Klinisch: Zellkultur- und Tierexperiemente
|
| AEG35156 | | XIAP Antagonist | Aegera |
|
| Aequorin | | | Quincy Bioscience |
|
| Arvanil | | Capsaicin-Anandamid-Hybrid | |
|
| AT-008 | | | Androclus |
|
| AZD 8797 | | | AstraZeneca |
|
| Bowmann-Birk Inhibitor Konzentrat | | | Jefferson Medical College |
|
| Calpeptin | | Calpain-Hemmer | Univ. of South Carolina |
|
| Cathepsin S | | | Medivir |
|
| CD3 Antikörper | | | Harvard Univ. |
|
| CD83 | | | Argos Therapeutics |
|
| CEP-701 | | | Johns Hopkins |
|
| CF101 | | | Can Fite BioPharma |
|
| CF402 | | | Can Fite BioPharma |
|
| CGEN-54 | | | Compugen |
|
| CHR-1103 | | | Chromos |
|
| CNTF | | Ciliary neurotrophic factor | |
|
| CRA-028129 | | cathepsin S inhibitor | Schering |
|
| CYLA | | calpain inhibitor | SUNY Downstate Medical Center |
|
| Phenytoin | Dilantin® | | Yale University |
|
| DZ2002 | | | Shanghai Institute of Materia Medica |
|
| Exon Skipping Pre-RNA Interference | | | AVI BioPharma |
|
| Estrogen receptor alpha ligand | | | UCLA |
|
| Fasudil | | | Kyushu University |
|
| Gemfibrozil | Lopid® | | Rush University |
|
| GEMS-001 | | | Gemacbio |
|
| GGF2 | | Glial Growth Factor 2 | Acorda |
|
| Glucosamine | | | Thomas Jefferson University |
|
| hBCMA-Fc | | | La Trobe University - Australia |
|
| HE3204 | | | Hollis-Eden |
|
| | | IL-1ra gene therapy | San Raffaele Sci.Inst., Milan |
|
| LF 15-0195 | | | Univ. Paul Sabatier, France |
|
| LJP 1207 | | | La Jolla Pharmaceuticals |
|
| LLDT-8 | | | Chinese Academy of Sciences |
|
| LX2931 | | | Lexicon Genetics |
|
| MCT-175 | | | MultiCell |
|
| Mikbeta1 | | | NIH |
|
| MTA (methylthioadenosine) | | | Univ. of Navarra - Spain |
|
| MT203 | | human anti-GM-CSF IgG1 antibody | Micromet AG |
|
| NAPVSIPQ (NAP) | | | Allon |
|
| Neurodur | | | Ceptor |
|
| Neutrazumab | | C5a Receptor antagonist | G2 Therapies |
|
| Nicotinamid | | | Children's Hospital - Boston |
|
| ONO-2506 | | arundic acid | Takizawa et al |
|
| OPN-101 | | | Opsona |
|
| Osteopontin | | | Serono |
|
| COG133 | | apoE-Proteinmimetikum | | Duke Univ.
|
| PLP-BPI | | | University of Kansas |
|
| PXS25 | | | Pharmaxis |
|
| PXS64 | | | Pharmaxis |
|
| PXS2076 | | | Pharmaxis |
|
| Q-Cells | | | Q Therapeutics |
|
| QR-442 | | | Quigley |
|
| R348 | | | Rigel |
|
| ROB 895 | | | Oxypharma |
|
| ShK(L5) | | | UC Irvine |
|
| STA-5326 | | | Synta Pharmaceuticals |
|
| sTNFR:Fc/p80 | | | Med. Univ. of Lodz, Poland |
|
| Symadex | | Imidazoacridinone | Xanthus |
|
| Interferon-beta Inhalation | | | Syntonix/Serono |
|
| Tetracycline | | ohne antibiotische Wirkung | Paratek |
|
| Timcodar | | | Recovexx |
|
| Vasoactive Intestinal Peptide | | | |
|
| VX15 | | | Vaccinex / Teva |
|
| 13-cis-retinoic acid | | | Kinemed |
|
| 15d-PGJ(2) | | | Univ. of Arkansas |
|
| AICAR | | | Univ. of South Carolina |
|
